Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $6,045 | 406 | 99.8% |
| Education | $10.41 | 4 | 0.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Sunovion Pharmaceuticals Inc. | $1,381 | 123 | $0 (2021) |
| ABBVIE INC. | $666.68 | 39 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $496.72 | 30 | $0 (2023) |
| Otsuka America Pharmaceutical, Inc. | $342.98 | 19 | $0 (2024) |
| Lilly USA, LLC | $338.72 | 20 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $318.58 | 19 | $0 (2022) |
| Allergan, Inc. | $304.09 | 29 | $0 (2020) |
| PFIZER INC. | $280.90 | 16 | $0 (2024) |
| Novo Nordisk Inc | $276.68 | 16 | $0 (2020) |
| AstraZeneca Pharmaceuticals LP | $185.04 | 12 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $389.78 | 22 | ABBVIE INC. ($73.94) |
| 2023 | $716.20 | 38 | AbbVie Inc. ($206.46) |
| 2022 | $725.07 | 40 | Regeneron Healthcare Solutions, Inc. ($200.68) |
| 2021 | $919.28 | 61 | AbbVie Inc. ($268.32) |
| 2020 | $937.96 | 64 | Sunovion Pharmaceuticals Inc. ($286.43) |
| 2019 | $512.17 | 45 | Sunovion Pharmaceuticals Inc. ($235.89) |
| 2018 | $1,099 | 86 | Sunovion Pharmaceuticals Inc. ($460.22) |
| 2017 | $756.45 | 54 | Sunovion Pharmaceuticals Inc. ($306.83) |
All Payment Transactions
410 individual payment records from CMS Open Payments — Page 1 of 17
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $14.33 | General |
| Category: Gastroenterology | ||||||
| 12/12/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $16.46 | General |
| Category: PSYCHIATRY | ||||||
| 12/06/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $18.20 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/04/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $19.01 | General |
| Category: Respiratory | ||||||
| 11/25/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $15.69 | General |
| Category: PAIN | ||||||
| 11/04/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $15.43 | General |
| Category: PSYCHIATRY | ||||||
| 10/09/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $13.77 | General |
| Category: PSYCHIATRY | ||||||
| 08/21/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $17.31 | General |
| Category: NEUROSCIENCE | ||||||
| 07/11/2024 | Tolmar, Inc. | JATENZO (Drug) | Food and Beverage | Cash or cash equivalent | $20.48 | General |
| Category: HORMONE REPLACEMENT | ||||||
| 07/08/2024 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Food and Beverage | In-kind items and services | $20.00 | General |
| Category: Neuroscience | ||||||
| 06/13/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $20.82 | General |
| Category: PSYCHIATRY | ||||||
| 04/25/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $19.38 | General |
| Category: NEUROSCIENCE | ||||||
| 04/16/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $18.21 | General |
| Category: Respiratory | ||||||
| 04/03/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $17.76 | General |
| Category: Gastroenterology | ||||||
| 03/28/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $14.57 | General |
| Category: Diabetes | ||||||
| 03/14/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $18.67 | General |
| Category: PSYCHIATRY | ||||||
| 03/12/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $16.05 | General |
| Category: NEUROSCIENCE | ||||||
| 03/04/2024 | PFIZER INC. | PREVNAR 20 (Biological), COMIRNATY, ABRYSVO | Food and Beverage | In-kind items and services | $19.87 | General |
| Category: VACCINES | ||||||
| 02/22/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $21.20 | General |
| Category: NEUROSCIENCE | ||||||
| 02/06/2024 | Tolmar, Inc. | JATENZO (Drug) | Food and Beverage | Cash or cash equivalent | $18.68 | General |
| Category: HORMONE REPLACEMENT | ||||||
| 02/05/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $18.00 | General |
| Category: PSYCHIATRY | ||||||
| 01/09/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $15.89 | General |
| Category: PSYCHIATRY | ||||||
| 12/13/2023 | IDORSIA PHARMACEUTICALS US INC | QUVIVIQ (Drug) | Food and Beverage | In-kind items and services | $9.71 | General |
| Category: INSOMNIA | ||||||
| 12/04/2023 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug), TRULANCE | Food and Beverage | In-kind items and services | $14.79 | General |
| Category: Gastroenterology | ||||||
| 11/30/2023 | IDORSIA PHARMACEUTICALS US INC | QUVIVIQ (Drug) | Food and Beverage | In-kind items and services | $9.70 | General |
| Category: INSOMNIA | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 283 | 634 | $107,378 | $51,525 |
| 2022 | 9 | 442 | 1,125 | $151,889 | $78,065 |
| 2021 | 11 | 476 | 1,243 | $153,072 | $73,900 |
| 2020 | 10 | 446 | 1,280 | $116,066 | $56,454 |
All Medicare Procedures & Services
36 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 125 | 209 | $58,290 | $27,749 | 47.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 47 | 224 | $25,045 | $13,426 | 53.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 43 | 78 | $9,307 | $5,188 | 55.7% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 26 | 51 | $13,616 | $4,558 | 33.5% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 28 | 41 | $410.00 | $344.40 | 84.0% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 14 | 31 | $709.82 | $260.25 | 36.7% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 154 | 252 | $71,972 | $38,688 | 53.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 81 | 415 | $47,725 | $25,808 | 54.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 67 | 141 | $19,035 | $10,341 | 54.3% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 14 | 23 | $5,451 | $1,262 | 23.2% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 12 | 14 | $4,228 | $1,123 | 26.6% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 28 | 60 | $1,372 | $547.46 | 39.9% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 55 | 95 | $950.00 | $281.43 | 29.6% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2022 | 20 | 112 | $896.00 | $9.44 | 1.1% |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | Office | 2022 | 11 | 13 | $260.00 | $4.34 | 1.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 91 | 535 | $61,525 | $33,710 | 54.8% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 98 | 105 | $30,829 | $16,476 | 53.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 57 | 109 | $14,715 | $9,663 | 65.7% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 53 | 95 | $28,641 | $7,686 | 26.8% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 35 | 50 | $8,805 | $2,817 | 32.0% |
| G0438 | Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | Office | 2021 | 14 | 14 | $2,250 | $2,250 | 100.0% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2021 | 27 | 89 | $2,035 | $869.52 | 42.7% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2021 | 54 | 74 | $740.00 | $222.00 | 30.0% |
| 93000 | Routine ekg using at least 12 leads including interpretation and report | Office | 2021 | 15 | 17 | $1,020 | $180.59 | 17.7% |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | Office | 2021 | 11 | 37 | $1,235 | $15.14 | 1.2% |
About Dr. John Barton, MD
Dr. John Barton, MD is a Internal Medicine healthcare provider based in Slidell, Louisiana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/14/2006. The National Provider Identifier (NPI) number assigned to this provider is 1841233095.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Barton, MD has received a total of $6,056 in payments from pharmaceutical and medical device companies, with $389.78 received in 2024. These payments were reported across 410 transactions from 39 companies. The most common payment nature is "Food and Beverage" ($6,045).
As a Medicare-enrolled provider, Barton has provided services to 1,647 Medicare beneficiaries, totaling 4,282 services with total Medicare billing of $259,944. Data is available for 4 years (2020–2023), covering 36 distinct procedure/service records.
Practice Information
- Specialty Internal Medicine
- Other Specialties Internal Medicine
- Location Slidell, LA
- Active Since 06/14/2006
- Last Updated 01/19/2026
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1841233095
Products in Payments
- VRAYLAR (Drug) $878.43
- LONHALA MAGNAIR (Drug) $568.44
- DUPIXENT (Biological) $496.72
- BROVANA (Drug) $337.97
- REXULTI (Drug) $327.21
- Utibron (Drug) $217.11
- CAPLYTA (Drug) $201.16
- UTIBRON (Drug) $173.88
- QUVIVIQ (Drug) $168.39
- Vimpat (Drug) $145.39
- VYVANSE (Drug) $141.26
- Victoza (Drug) $136.68
- COLOGUARD (Device) $126.78
- TRINTELLIX (Drug) $119.23
- EMGALITY (Drug) $113.13
- Trintellix (Drug) $102.65
- XIFAXAN (Drug) $101.78
- Movantik (Drug) $99.48
- TRULICITY (Drug) $91.48
- LATUDA (Drug) $83.72
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Slidell
Omer Iftikhar, Ms, MS
Internal Medicine — Payments: $19,182
Dr. Allan Larcena, Md, MD
Internal Medicine — Payments: $18,744
Christy Graves, M.d, M.D
Internal Medicine — Payments: $13,780
Mr. Abhishek Garg, M.d, M.D
Internal Medicine — Payments: $12,235
Dr. Sanjay Raina, M.d, M.D
Internal Medicine — Payments: $9,333
Pedro Serrant, M.d, M.D
Internal Medicine — Payments: $8,338